About Neogen (NASDAQ:NEOG)
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed, and grain processors and processors; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topical and diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
Trailing P/E Ratio95.27
Forward P/E Ratio69.43
Sales & Book Value
Annual Sales$361.59 million
Price / Sales11.69
Cash Flow$1.1513 per share
Price / Cash71.16
Book Value$9.28 per share
Price / Book8.83
EPS (Most Recent Fiscal Year)$0.86
Net Income$43.79 million
Return on Equity11.49%
Return on Assets10.31%
Neogen (NASDAQ:NEOG) Frequently Asked Questions
What is Neogen's stock symbol?
Neogen trades on the NASDAQ under the ticker symbol "NEOG."
When did Neogen's stock split? How did Neogen's stock split work?
Neogen shares split on the morning of Tuesday, January 2nd 2018. The 4-3 split was announced on Friday, December 8th 2017. The newly minted shares were distributed to shareholders after the closing bell on Friday, December 29th 2017. An investor that had 100 shares of Neogen stock prior to the split would have 133 shares after the split.
How were Neogen's earnings last quarter?
Neogen Co. (NASDAQ:NEOG) announced its quarterly earnings data on Thursday, March, 22nd. The company reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.24 by $0.08. The company had revenue of $95.90 million for the quarter, compared to the consensus estimate of $97.93 million. Neogen had a return on equity of 11.49% and a net margin of 14.82%. The firm's quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.27 earnings per share. View Neogen's Earnings History.
When is Neogen's next earnings date?
What price target have analysts set for NEOG?
4 brokerages have issued 1 year price targets for Neogen's shares. Their predictions range from $60.00 to $65.00. On average, they anticipate Neogen's stock price to reach $62.3333 in the next year. View Analyst Ratings for Neogen.
Who are some of Neogen's key competitors?
Some companies that are related to Neogen include IPSEN S A/S (IPSEY), Immunomedics (IMMU), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML) and ImmuCell (ICCC).
Who are Neogen's key executives?
Neogen's management team includes the folowing people:
- Mr. James L. Herbert, Exec. Chairman (Age 78)
- Mr. Steven J. Quinlan, VP, CFO & Sec. (Age 56)
- Ms. Terri A. Morrical, VP of Animal Safety Operations (Age 53)
- Mr. John Edward Adent, Pres & CEO (Age 50)
- Mr. Rod Poland, Director of Corp. Communications
Has Neogen been receiving favorable news coverage?
Media headlines about NEOG stock have trended somewhat positive on Monday, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Neogen earned a media sentiment score of 0.14 on Accern's scale. They also assigned news articles about the company an impact score of 47.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Neogen's major shareholders?
Neogen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.54%), Wasatch Advisors Inc. (3.87%), New York State Common Retirement Fund (2.02%), King Luther Capital Management Corp (1.86%), PNC Financial Services Group Inc. (1.84%) and Stephens Investment Management Group LLC (1.82%). Company insiders that own Neogen stock include Edward Bradley, G Bruce Papesh, Jack C Parnell, James L Herbert, James P Tobin, Richard E Calk, Jr, Ronald D Green, Steven J Quinlan, Terri A Morrical, Thomas H Reed and William T Boehm. View Institutional Ownership Trends for Neogen.
Which major investors are selling Neogen stock?
NEOG stock was sold by a variety of institutional investors in the last quarter, including Tiverton Asset Management LLC, Millennium Management LLC, Glen Harbor Capital Management LLC, Envestnet Asset Management Inc., Citigroup Inc., Flinton Capital Management LLC, Boston Family Office LLC and Teacher Retirement System of Texas. Company insiders that have sold Neogen company stock in the last year include Edward Bradley, G Bruce Papesh, James L Herbert, Ronald D Green, Steven J Quinlan, Terri A Morrical, Thomas H Reed and William T Boehm. View Insider Buying and Selling for Neogen.
Which major investors are buying Neogen stock?
NEOG stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wasatch Advisors Inc., King Luther Capital Management Corp, Stephens Investment Management Group LLC, New York State Common Retirement Fund, Northern Trust Corp, Wells Fargo & Company MN and Dimensional Fund Advisors LP. View Insider Buying and Selling for Neogen.
How do I buy shares of Neogen?
Shares of NEOG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neogen's stock price today?
One share of NEOG stock can currently be purchased for approximately $81.93.
How big of a company is Neogen?
Neogen has a market capitalization of $4.22 billion and generates $361.59 million in revenue each year. The company earns $43.79 million in net income (profit) each year or $0.86 on an earnings per share basis. Neogen employs 1,413 workers across the globe.
How can I contact Neogen?
Neogen's mailing address is 620 LESHER PLACE, LANSING MI, 48912. The company can be reached via phone at 517-372-9200 or via email at [email protected]
MarketBeat Community Rating for Neogen (NEOG)MarketBeat's community ratings are surveys of what our community members think about Neogen and other stocks. Vote "Outperform" if you believe NEOG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEOG will underperform the S&P 500 over the long term. You may vote once every thirty days.